Table 2 Number of trials for agents with varying mechanisms of action
From: Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Year registered | Symptomatic for cognition | Symptomatic for behavior | Disease-modifying small molecule | Disease-modifying immunotherapy | Therapeutic device | Stem cells | Total |
|---|---|---|---|---|---|---|---|
2002 | 1 | 3 | 0 | 1 | 0 | 0 | 5 |
2003 | 5 | 1 | 4 | 0 | 2 | 0 | 12 |
2004 | 5 | 2 | 6 | 0 | 1 | 0 | 14 |
2005 | 10 | 3 | 16 | 3 | 0 | 0 | 32 |
2006 | 12 | 1 | 8 | 4 | 0 | 0 | 25 |
2007 | 18 | 1 | 17 | 10 | 0 | 0 | 46 |
2008 | 23 | 1 | 18 | 15 | 4 | 0 | 61 |
2009 | 31 | 2 | 19 | 17 | 2 | 1 | 72 |
2010 | 11 | 2 | 23 | 13 | 2 | 0 | 51 |
2011 | 17 | 2 | 17 | 5 | 3 | 1 | 45 |
2012 | 18 | 4 | 17 | 8 | 2 | 1 | 50 |
Total | 151 | 22 | 145 | 76 | 16 | 3 | 413 |
Percent | 36.56 | 5.33 | 35.11 | 18.40 | 3.87 | 0.73 | 100 |